Literature DB >> 7049706

Effects of once daily indapamide and pindolol on blood pressure, plasma aldosterone concentration and plasma renin activity in a general practice setting.

J P Chalmers, L M Wing, J J Grygiel, M J West, J R Graham, A J Bune.   

Abstract

Sixteen patients with essential hypertension completed a double blind factorial trial comparing the effects of indapamide (2.5 mg daily) and pindolol (10 mg daily) on blood pressure, heart rate, plasma renin activity and plasma aldosterone concentration. There were four randomised test phases of eight weeks each during which patients received indapamide alone, pindolol alone, indapamide plus pindolol and no active treatment (placebo). Blood pressure and heart rate were measured every two weeks. Supine mean arterial pressure fell from 117 mm Hg in the placebo phase to 111 mm Hg in the indapamide phase, 106 mm Hg in the pindolol phase and 103 mm Hg in the combined indapamide plus pindolol phase. Factorial analysis confirmed that the hypotensive effects of the two drugs were additive, without evidence of potentiation or antagonism. Indapamide caused significant reductions in plasma potassium and chloride, and increases in plasma bicarbonate and urate concentrations; it also caused increases in plasma renin activity and aldosterone concentration. These changes are similar to those observed with thiazide diuretics.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7049706     DOI: 10.1007/bf00545213

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  The role of renin in the antihypertensive action of beta-adrenoreceptor blocking agents.

Authors:  G S Stokes; R M Graham; M A Weber
Journal:  Drugs       Date:  1976       Impact factor: 9.546

2.  A non-chromatographic non-extraction radioimmunoassay for serum aldosterone.

Authors:  T Ogihara; K Iinuma; K Nishi; Y Arakawa; A Takagi
Journal:  J Clin Endocrinol Metab       Date:  1977-10       Impact factor: 5.958

3.  Comparison of indapamide with thiazide diuretics in patients with essential hypertension.

Authors:  J P Chalmers; A J Bune; J R Graham; M J West; L M Wing
Journal:  Med J Aust       Date:  1981-07-25       Impact factor: 7.738

4.  Change in symptoms of hypertensive patients after referral to hospital clinic.

Authors:  C J Bulpitt; C T Dollery; S Carne
Journal:  Br Heart J       Date:  1976-02

5.  Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group.

Authors: 
Journal:  JAMA       Date:  1979-12-07       Impact factor: 56.272

6.  Double-blind factorial trial of prindolol and hydrochlorothiazide in hypertension.

Authors:  J P Chalmers; P I Korner; D J Tiller; A J Bune; J D Steiner; M J West; L M Wing; J F Uther
Journal:  Med J Aust       Date:  1976-05-01       Impact factor: 7.738

7.  Side effects of hypotensive agents evaluated by a self-administered questionnaire.

Authors:  C J Bulpitt; C T Dollery
Journal:  Br Med J       Date:  1973-09-01

8.  Hypertension due to a renin-secreting tumour localised by segmental renal vein sampling.

Authors:  J M Bonnin; M D Cain; J S Jose; T M Mukherjee; L V Perrett; G C Scroop; A E Seymour
Journal:  Aust N Z J Med       Date:  1977-12

9.  Effects of timolol and hydrochlorothiazide on blood-pressure and plasma renin activity. Double-blind factorial trial.

Authors:  J Chalmers; D Tiller; J Horvath; A Bune
Journal:  Lancet       Date:  1976-08-14       Impact factor: 79.321

10.  The Australian therapeutic trial in mild hypertension. Report by the Management Committee.

Authors: 
Journal:  Lancet       Date:  1980-06-14       Impact factor: 202.731

View more
  1 in total

1.  Indapamide. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension.

Authors:  M Chaffman; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.